AHA Clears Path for Exercise in Kids With Cardiomyopathy
A landmark AHA statement challenges decades of blanket activity restrictions for children with cardiomyopathy, offering new risk-stratified guidance.
Summary
For years, children with cardiomyopathy were routinely told to avoid physical activity due to fears of sudden cardiac death. A new American Heart Association scientific statement challenges this approach. Emerging evidence suggests that exercise restriction may actually harm these children by promoting sedentary behavior, poor fitness, and secondary metabolic disease — without necessarily reducing cardiac risk. The statement provides updated, individualized frameworks for safely engaging kids with hypertrophic, dilated, restrictive, and arrhythmogenic cardiomyopathy in physical activity. It incorporates advanced imaging, exercise testing, and genetic data to guide risk stratification, and emphasizes shared decision-making between clinicians, patients, and families. The conclusion: most children with cardiomyopathy can and should exercise safely.
Detailed Summary
For decades, children diagnosed with cardiomyopathy have faced sweeping restrictions on physical activity, driven by fears that exercise could trigger sudden cardiac death or accelerate disease progression. This cautious approach, while well-intentioned, has had measurable consequences: sedentary lifestyles, reduced cardiorespiratory fitness, and elevated risk of secondary cardiometabolic conditions among an already vulnerable pediatric population.
This 2026 American Heart Association scientific statement directly challenges that restrictive paradigm. Authored by a multidisciplinary committee spanning pediatric cardiology, sports medicine, and cardiovascular nursing, the document synthesizes emerging evidence across four major cardiomyopathy subtypes: hypertrophic (HCM), dilated (DCM), restrictive (RCM), and arrhythmogenic (ACM). It also addresses children living with implantable cardioverter defibrillators (ICDs).
Key findings from the reviewed evidence suggest that the risk of sudden cardiac death during exercise may not be meaningfully elevated in some cardiomyopathy patients compared to sedentary counterparts. Furthermore, physical activity may actively support reverse cardiac remodeling — a finding with significant therapeutic implications. The statement outlines how cardiovascular, emotional, and social benefits of exercise apply to these children just as they do to healthy peers.
The framework introduced emphasizes individualized risk stratification using advanced cardiac imaging, structured exercise testing, and genotype-specific data — moving away from blanket restrictions toward precision-guided participation. Shared decision-making, tailored to the child's developmental stage and family priorities, is positioned as central to clinical practice. Longitudinal monitoring is also stressed, given that clinical phenotypes in pediatric cardiomyopathy can evolve over time.
The practical implication is significant: most children and adolescents with cardiomyopathy can safely participate in physical activity when properly evaluated. Clinicians are encouraged to shift from default restriction to individualized engagement, with the long-term goal of improving both cardiometabolic and psychological health outcomes in this population.
Key Findings
- Exercise restriction in pediatric cardiomyopathy may increase cardiometabolic risk without meaningfully reducing sudden cardiac death risk.
- Physical activity may promote reverse cardiac remodeling in some children with cardiomyopathy.
- Updated risk stratification using advanced imaging, exercise testing, and genotype data enables safer, individualized activity guidance.
- Most children with HCM, DCM, RCM, or ACM — including ICD recipients — can safely engage in physical activity.
- Shared decision-making and longitudinal surveillance are essential as pediatric cardiac phenotypes evolve over time.
Methodology
This is an evidence-based scientific statement from the American Heart Association, not a primary research study. It synthesizes existing literature across pediatric cardiomyopathy subtypes and was developed by a multidisciplinary expert committee. The statement reflects consensus guidance informed by clinical data, imaging studies, exercise testing research, and genetic evidence.
Study Limitations
This summary is based on the abstract only, as the full text is not open access; specific risk thresholds, imaging criteria, and genotype-specific recommendations could not be reviewed. As a scientific statement rather than a systematic review or meta-analysis, the evidence synthesis methodology and grading of individual recommendations are not fully assessable from the abstract alone. The statement's applicability to adult cardiomyopathy populations is not addressed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.